Holotomography meets microfluidics: Advancing patient-derived organoid drug screening

Online Webinar - Presentation

-

Thursday 11 December 2025 - 15:00

Holotomography meets microfluidics: Advancing patient-derived organoid drug screening
Post publication date: 
Monday, December 1, 2025

Tomocube and Okomera joint webinar to unveil integrated workflow for functional precision medicine

We are excited to announce an upcoming joint webinar with Okomera, a pioneer in droplet-based microfluidic organoid screening, titled “Holotomography Meets Microfluidics: Patient-derived organoid drug screening.” Scheduled for December 11, 2025, this session will showcase how the combination of label-free 3D holotomography and high-throughput microfluidics can transform preclinical drug testing and functional precision oncology.

Webinar Overview

The webinar will bring together experts from both companies to present a synergistic workflow that addresses key challenges in organoid-based drug screening: preserving tumor heterogeneity, enabling label-free longitudinal imaging, and extracting quantitative, clinically relevant insights. Attendees will learn how the integration of Tomocube’s HT-X1 Plus holotomography system and Okomera’s microfluidic Ocentra platform provides a powerful solution for evaluating drug responses in patient-derived tumor organoids with unprecedented detail and throughput.

Speakers & Agenda
  • Lucile Mercier (Okomera): Ex vivo modelling of therapeutic tumor response using microfluidic technology

  • Joey Lee (Tomocube): From images to insights: quantitative analysis with TomoAnalysis

  • Bruno Combettes (Tomocube): Opening moderation and Q&A facilitation

Why This Matters

Patient-derived organoids (PDOs) have emerged as a physiologically relevant model for drug discovery and personalized medicine. However, conventional workflows often rely on endpoint assays and staining, which can miss dynamic changes and microenvironmental influences. The combined approach presented in this webinar offers:

  • Label-free, non-invasive 3D imaging of living organoids over days

  • High-throughput multiplexed screening from minimal biopsy material

  • AI-powered quantitative analysis of tumor-stroma heterogeneity and drug response

  • Stroma-aware sensitivity profiling, revealing microenvironment-mediated resistance

Related products 

Holotomographic Microscope for 3D Label-Free Imaging of Samples
Compact design with flexible configuration; advanced Holotomography imaging accessible for every lab.
High-Performance Holotomography microscope for imaging at scale

Partner 

Tomocube, Inc